Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer.
Journal: JAMA network open
Published: June 29, 2026
Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer.
Journal: JAMA network open
Published: June 24, 2026
Real-world Effectiveness of Single-Agent Tivozanib in Patients with Metastatic Clear Cell Renal Cell Carcinoma.
Journal: Journal of kidney cancer and VHL
Published: March 27, 2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.
Journal: Bladder cancer (Amsterdam, Netherlands)
Published: January 09, 2026
Metastatic prostate cancer: Clinical trials to watch.
Journal: Med (New York, N.Y.)
Published: October 23, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.
Journal: JAMA network open
Published: October 02, 2025
Antibody-drug conjugates in prostate cancer: current landscape and future directions.
Journal: Therapeutic advances in medical oncology
Published: September 08, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US.
Journal: JAMA network open
Published: March 20, 2025
Metastatic renal cell carcinoma disease response in the era of immune checkpoint inhibitor-based combinations.
Journal: Translational andrology and urology
Published: February 09, 2025
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma.
Journal: Journal of kidney cancer and VHL
Published: December 09, 2024
Showing 1-12 of 12
Last Updated: 09/26/2026